A5040482537- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Renal cell carcinoma treatment
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- Monoclonal and Polyclonal Antibodies Research
- Pancreatic and Hepatic Oncology Research
- Peptidase Inhibition and Analysis
- Bladder and Urothelial Cancer Treatments
- Renal and related cancers
- Testicular diseases and treatments
- Tryptophan and brain disorders
- Cancer, Hypoxia, and Metabolism
- Gastric Cancer Management and Outcomes
- Prostate Cancer Diagnosis and Treatment
- Palliative Care and End-of-Life Issues
- Neuroinflammation and Neurodegeneration Mechanisms
- Epigenetics and DNA Methylation
- Multiple and Secondary Primary Cancers
- Lung Cancer Diagnosis and Treatment
- Economic and Financial Impacts of Cancer
National University Cancer Institute, Singapore
2013-2025
VA San Diego Healthcare System
2024-2025
University of California, San Diego
2024-2025
National University Hospital
2001-2023
National University of Singapore
2011-2021
Weatherford College
2021
National University Health System
2010-2020
Massachusetts General Hospital
2007
Methodist Richardson Medical Center
2006
The utility of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte (PLR) in predicting immune-related adverse events (irAEs) survival have not been well studied the context treatment with immune checkpoint inhibitors (ICIs). We performed a case-control study cancer patients who received at least one dose ICI tertiary hospital. examined NLR PLR irAE cases controls. Logistic Cox regression models were used to identify independent risk factors for irAEs, progression-free (PFS),...
Abstract Purpose: Safety and efficacy of acapatamab, a prostate-specific membrane antigen (PSMA) x CD3 bispecific T-cell engager were evaluated in first-in-human study metastatic castration-resistant prostate cancer (mCRPC). Patients Methods: with mCRPC refractory to androgen receptor pathway inhibitor therapy taxane-based chemotherapy received target acapatamab doses ranging from 0.003 0.9 mg dose exploration (seven levels) 0.3 (recommended phase II dose) expansion intravenously every 2...
Mutations or silencing of the von Hippel Lindau (VHL) tumor suppressor gene accumulates hypoxia-inducible factors (HIFs). HIF-2α is implicated in oncogenesis ~50% patients with clear cell renal carcinoma (ccRCC) but, has been considered "undruggable". DFF332, an orally administered novel allosteric inhibitor showed dose-dependent antitumor efficacy preclinical models ccRCC. This first-in-human study evaluated safety, tolerability, activity, pharmacokinetics, and pharmacodynamics DFF332...
Research Article30 May 2018Open Access Transparent process Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies non-small cell lung cancer Dana Wai Yi Tsui orcid.org/0000-0002-0595-6664 Cancer UK Cambridge Institute, Li Ka Shing Centre, University Cambridge, Major Center - Search for more papers by this author Muhammed Murtaza Department Oncology, Alvin Seng Cheong Wong Haematology-Oncology, National Health System, Singapore, Singapore Oscar M Rueda...
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines diagnosis, treatment and follow-up prostate cancer was published in 2020. It therefore decided, by both ESMO Singapore (SSO), to convene a special, virtual guidelines meeting November 2021 adapt 2020 take into account differences associated with Asia. These represent consensus opinions reached experts patients representing oncological societies China (CSCO), India (ISMPO), Japan (JSMO),...
Abstract Background Durvalumab consolidation is associated with improved survival following concurrent chemoradiotherapy (CCRT) in patients stage III non‐small cell lung cancer (NSCLC). Given the heterogeneity of NSCLC patients, this study we evaluated efficacy and safety durvalumab real‐world setting. Method Unresectable were retrospectively studied: one cohort received CCRT, another had CCRT‐durvalumab. Primary endpoints progression‐free (PFS) overall (OS), secondary relapse rate safety....
The exact clinical course and factors associated with persistent endocrine immune-related adverse events (irAEs) are not well-established. Elucidation of these information will aid irAEs screening follow-up planning for patients on immunotherapy. We analysed the including thyroid pituitary dysfunction insulin-dependent diabetes mellitus (IDDM), identified dysfunction, determined association between survival parameters. This retrospective observational study enrolled metastatic cancer who...
Immune-related adverse events (IrAEs) of immune checkpoint inhibitors (ICIs) can be serious and unpredictable. We examine the incidence rate risk factors for IrAEs in an Asian cohort nonsmall cell lung cancer (NSCLC) patients treated with immunotherapy. Between June 2014 August 2020, we retrospectively analysed NSCLC anti-PD-1 or anti-PD-L1 at National University Cancer Institute, Singapore. A Poisson regression model was used to estimate effect on any grade IrAEs. One hundred forty-one were...
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines diagnosis, treatment and follow-up renal cell carcinoma was published in 2019 with an update planned 2021. It therefore decided by both ESMO Singapore (SSO) to convene a special, virtual guidelines meeting May 2021 adapt take into account ethnic differences associated carcinomas Asian patients. These represent consensus opinions reached experts patients representing oncological societies...
Primary resistance to immune checkpoint inhibitors (ICI) is observed in routine clinical practice. We sought determine factors predictive of primary ICI monotherapy, defined by the Society for Immunotherapy Cancer (SITC) as progression within 6 months treatment with patients receiving at least weeks advanced non-small-cell lung cancer (NSCLC).Patients stage IV NSCLC treated single-agent two tertiary hospitals Singapore were included. A multivariate logistic regression model was utilised...
4513 Background: Targeting HIF2α inhibition has been proven to be an effective therapeutic option in patients (pts) with advanced clear cell renal carcinoma (ccRCC). DFF332, a small molecule inhibitor that selectively targets transcriptional activity, shown dose-dependent antitumor efficacy preclinical models of ccRCC. Methods: This is the first human, Phase I/Ib, open-label, multicenter, study (CDFF332A12101, NCT04895748) DFF332 adult pts The evaluated safety, tolerability, pharmacokinetics...
<b><i>Background:</i></b> The approved doses of the single agent nivolumab – an anti-programmed cell death protein 1 (PD-1) monoclonal antibody for renal carcinoma (RCC) are 3 mg/kg and a 240-mg flat dose, despite efficacy shown at lower in earlier CheckMate trials. In view financial constraints, minimum dose required remains critical area inquiry. <b><i>Methods:</i></b> A retrospective review RCC patients receiving single-agent anti-PD-1...
ABSTRACT With the many negative health consequences of cigarette smoking, quitting is known to improve in multiple domains. Using positron emission tomography/computed tomography (PET/CT) scanning, our group previously demonstrated that smokers have lower levels than nonsmokers translocator protein binding both acutely and following overnight abstinence. Here, we sought determine effects longer smoking abstinence on this marker gliosis for microglia astroglia, as well explore associations...
ABSTRACT Aims Gallium‐68 ( 68 Ga) prostate‐specific membrane antigen (PSMA) ([ Ga]Ga‐PSMA‐11) directed PET/CT reflects PSMA expression at metastatic sites and can hence be a surrogate of lutetium‐177 177 Lu) Lu]Lu‐PSMA) radiation delivery. This retrospective analysis aims to explore the association between quantitative baseline [ Ga]Ga‐PSMA‐11 PET imaging biomarkers treatment outcomes in our Asian cohort. Methods We included patients with progressive castrate‐resistant prostate cancer...
<p>Supplementary Figure S1. Time to all grade TRAE at different doses of DFF332. This swimmer plot illustrates the timeline AE onset for each patient in study. The x-axis represents time days, while y-axis lists individual patients. Different colors denote dose level which was allocated, and symbols indicate when adverse events started. AE, event; QD, once daily; QW, weekly; TRAE, treatment-related event.</p>
<p>Key inclusion and exclusion criteria</p>
<div>AbstractPurpose:<p>Mutations or silencing of the von Hippel–Lindau tumor suppressor gene accumulate hypoxia-inducible factors (HIF). HIF-2α is implicated in oncogenesis ∼50% patients with clear-cell renal cell carcinoma (ccRCC) but has been considered “undruggable.” DFF332, an orally administered novel allosteric inhibitor HIF-2α, showed dose-dependent antitumor efficacy preclinical models ccRCC.</p>Patients and Methods:<p>This first-in-human study evaluated...
<p>Supplementary Figure S2. Comparison of percentage changes in patients’ plasma levels erythropoietin between baseline and cycle 3 day 1 (A) with respect to their BOR (B) against the change hemoglobin levels. Statistical comparison was performed using a two-sample t-test; p < 0.05 considered significant. Boxplot (Figure A): central line box, median; interquartile range (IQR; 25th 75th percentile); whiskers, smallest largest values within 1.5 times IQR from lower upper quartiles;...